Yasushi Samukawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yasushi Samukawa has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Hoshikawa
Kagawa University, Faculty of Medicine, Department of Otolaryngology, Kita-gun, Miki-cho, Japan
2 shared publications- Kosuke Akiyama
Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan
1 shared publication - Masataka Nakamura
Department of Neurology, Kansai Medical University, Hirakata, Japan
1 shared publication - Naoki Akisada
Department of Head and Neck Surgery National Cancer Center Hospital East Chiba Japan
1 shared publication - Nobuya Monden
Department of Head and Neck surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
1 shared publication - Satoshi Takahashi
Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan
1 shared publication
Latest Publications
- Open Access
- 9 July 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90 (5) , 101463
Is the measurement of ethmoid sinus dominance in eosinophilic chronic rhinosinusitis accurate?
- 9 July 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90 (5) , 101463
Open AccessIs the measurement of ethmoid sinus dominance in eosinophilic chronic rhinosinusitis accurate?
- Open Access
- 26 March 2021
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 102 (6) , 379-384
The Utility of Glasgow Prognostic Score and Palliative Prognostic Index in Patients With Head and Neck Squamous Cell Carcinoma Under Palliative Care
Palliative care patients with head and neck squamous cell carcinoma (HNSCC) often experience dysphagia and airway trouble; thus, each patient requires a specific palliative care plan based on their prognostication. However, no established specific prognostic tool performed on the day of starting end-of-life care is available for such patients. We assessed the accuracy of Glasgow prognostic score (GPS) and palliative prognostic index (PPI) and their combination to establish a specified prognostic tool for patients with HNSCC in end-of-life setting. A retrospective clinical chart review was undertaken on patients with HNSCC in end-of life setting who were decided in Kagawa University Hospital and National Hospital Organization Shikoku Cancer Center between April 2011 and March 2019. The patients were divided into 2 categories according to GPS (0-1 and 2) and PPI (groups A-B and C). These were combined into 4 categories (PPI group A-B and GPS score 0-1: good; PPI group A-B and GPS score 2: intermediate; PPI group C and GPS score 2: poor; and PPI group C and GPS score 0-1: others). The survival curves were compared for the former 3 categories. The median survival of the scores 0-1 and 2 on GPS were 114 (72-148) and 39 (25-52) days, respectively (P < .01). These of groups A-B and C on PPI were 79 (64-99) and 16 (9-29) days, respectively (P < .01). The median survival of the good, intermediate, and poor categories was 127 (73-149), 64 (44-80), and 15 (9-27) days, respectively (P < .01 among all categories). In this study, the survival of terminally ill patients with HNSCC can be predicted by the GPS, PPI, and their combination with sufficient probability.
- 26 March 2021
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 102 (6) , 379-384
Open AccessThe Utility of Glasgow Prognostic Score and Palliative Prognostic Index in Patients With Head and Neck Squamous Cell Carcinoma Under Palliative Care
Palliative care patients with head and neck squamous cell carcinoma (HNSCC) often experience dysphagia and airway trouble; thus, each patient requires a specific palliative care plan based on their prognostication. However, no established specific prognostic tool performed on the day of starting end-of-life care is available for such patients. We assessed the accuracy of Glasgow prognostic score (GPS) and palliative prognostic index (PPI) and their combination to establish a specified prognostic tool for patients with HNSCC in end-of-life setting. A retrospective clinical chart review was undertaken on patients with HNSCC in end-of life setting who were decided in Kagawa University Hospital and National Hospital Organization Shikoku Cancer Center between April 2011 and March 2019. The patients were divided into 2 categories according to GPS (0-1 and 2) and PPI (groups A-B and C). These were combined into 4 categories (PPI group A-B and GPS score 0-1: good; PPI group A-B and GPS score 2: intermediate; PPI group C and GPS score 2: poor; and PPI group C and GPS score 0-1: others). The survival curves were compared for the former 3 categories. The median survival of the scores 0-1 and 2 on GPS were 114 (72-148) and 39 (25-52) days, respectively (P < .01). These of groups A-B and C on PPI were 79 (64-99) and 16 (9-29) days, respectively (P < .01). The median survival of the good, intermediate, and poor categories was 127 (73-149), 64 (44-80), and 15 (9-27) days, respectively (P < .01 among all categories). In this study, the survival of terminally ill patients with HNSCC can be predicted by the GPS, PPI, and their combination with sufficient probability.